Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5214 as Adjunct Therapy in Major Depressive Disorder
NCT01152554Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of dexmecamylamine in major depressive disorder (MDD), sponsored by AstraZeneca. Primary endpoint: Adverse Events at 54 weeks. Started Jun 2010; status: completed.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01152554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01152554.